- Home
- COLL
as 11-15-2024 4:00pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.1B | IPO Year: | 2015 |
| Target Price: | $42.00 | AVG Volume (30 days): | 440.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.16 | EPS Growth: | 757.11 |
| 52 Week Low/High: | $25.07 - $42.29 | Next Earning Date: | 11-07-2024 |
| Revenue: | $599,245,000 | Revenue Growth: | 9.62% |
| Revenue Growth (this year): | 13.02% | Revenue Growth (next year): | 18.01% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Thomas B | COLL | EVP and Chief Medical Officer | Sep 13 '24 | Sell | $36.62 | 9,593 | $351,319.64 | 53,816 | |
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Sep 5 '24 | Sell | $38.26 | 20,225 | $773,791.80 | 122,561 |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest
Zacks
4 days ago
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Argus Research
4 days ago
COLL: Lowering target price to $33.00
GlobeNewswire
5 days ago
Collegium to Participate in Upcoming Investor Conferences
Simply Wall St.
8 days ago
Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
9 days ago
Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
Zacks
9 days ago
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
Zacks
9 days ago
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.